LC-MS/MS for identifying patients with CYP24A1 mutations

Clinical Chemistry

Volumn 62, Issue 1, 2016, Pages 236-242

  Ketha, Hemamalini ^a   Kumar, Rajiv ^b,c   Singh, Ravinder J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; COLECALCIFEROL 24 HYDROXYLASE; CREATININE; PARATHYROID HORMONE; CYP24A1 PROTEIN, HUMAN;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CREATININE BLOOD LEVEL; FEMALE; GENE MUTATION; HUMAN; HYPERCALCEMIA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; TANDEM MASS SPECTROMETRY; BLOOD; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; MUTATION;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; MUTATION; TANDEM MASS SPECTROMETRY; VITAMIN D3 24-HYDROXYLASE;

EID: 84954468592     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.244459     Document Type: Article

References (26)

1. DeLuca HF, ed. Historical perspective. New York: Academic Press/Elsevier; 2011.
2. DeLuca HF, Schnoes HK. Vitamin D: recent advances. Annu Rev Biochem 1983;52:411-39.
3. Blunt JW, DeLuca HF, Schnoes HK. 25-Hydroxycholecalciferol: a biologically active metabolite of vitamin D3. Biochemistry 1968;7:3317-22.
4. Suda T, DeLuca HF, Schnoes HK, Blunt JW. The isolation and identification of 25-hydroxyergocalciferol. Biochemistry 1969;8:3515-20.
5. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689S-96S.
6. Holick MF, Garabedian M, DeLuca HF. 1, 25-Dihydroxycholecalciferol: metabolite of vitamin D3 active on bone in anephric rats. Science 1972;176:1146-7.
7. Kumar R. The metabolism and mechanism of action of 1, 25-dihydroxyvitamin D3. Kidney Int 1986;30:793-803.
8. Holick MF, Schnoes HK, DeLuca HF, Gray RW, Boyle IT, Suda T. Isolation and identification of 24, 25-dihydroxycholecalciferol, a metabolite of vitamin D made in the kidney. Biochemistry 1972;11:4251-5.
9. Kumar R. Metabolism of 1, 25-dihydroxyvitamin D3. Physiol Rev 1984;64:478-504.
10. Audran M, Gross M, Kumar R. The physiology of the vitamin D endocrine system. Semin Nephrol 1986;6:4-20.
11. Audran M, Kumar R. The physiology and pathophysiology of vitamin D. Mayo Clin Proc 1985;60:851-66.
12. Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 2012;97:E423-7.
13. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011;365:410-21.
14. Nesterova G, Malicdan MC, Yasuda K, Sakaki T, Vilboux T, Ciccone C, et al. 1, 25-(OH) 2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol 2013;8:649-57.
15. Kaufmann M, Gallagher JC, Peacock M, Schlingmann K-P, Konrad M, DeLuca HF, et al. Clinical utility of simultaneous quantitation of 25-hydroxyvitamin d and 24, 25-dihydroxyvitamin d by LC-MS/MS involving derivatization with DMEQ-TAD. J Clin Endocrinol Metab 2014;99:2567-74.
16. Jacobs TP, Kaufman M, Jones G, Kumar R, Schlingmann KP, Shapses S, Bilezikian JP. A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab 2014; jc20133802.
17. Sayers AH, SJ Rice, P Hogg, JA Sayer. Searching for CYP24A1 mutations in cohorts of patients with calcium nephrolithiasis. OA Nephrology 2013;1:6.
18. Dowen FE, Sayers JA, Hynes AM, Sayer JA. CYP24A1 mutation leading to nephrocalcinosis. Kidney Int 2014;85:1475.
19. Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 2013;190:552-7.
20. Dauber A, Nguyen TT, Sochett E, Cole DEC, Horst R, Abrams SA, et al. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab 2012;97:E268-74.
21. Cashman KD, Hayes A, Galvin K, Merkel J, Jones G, Kaufmann M, et al. Significance of serum 24, 25-dihydroxyvitamin D in the assessment of vitamin D status: a double-edged sword? Clin Chem 2015;61:636-45.
22. Netzel BC, Cradic KW, Bro ET, Girtman AB, Cyr RC, Singh RJ, Grebe SK. Increasing liquid chromatographytandem mass spectrometry throughput by mass tagging: a sample-multiplexed high-throughput assay for 25-hydroxyvitamin D2 and D3. Clin Chem 2011;57:431-40.
23. Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1alpha, 25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. Clin Chem 2011;57:1279-85.
24. Wagner D, Hanwell HE, Schnabl K, Yazdanpanah M, Kimball S, Fu L, et al. The ratio of serum 24, 25-dihydroxyvitamin D (3) to 25-hydroxyvitamin D (3) is predictive of 25-hydroxyvitamin D (3) response to vitamin D (3) supplementation. J Steroid Biochem Mol Biol 2011;126:72-7.
25. Berg AH, Powe CE, Evans MK, Wenger J, Ortiz G, Zonderman AB, et al. 24, 25-Dihydroxyvitamin D3 and vitamin D status of community-dwelling black and white Americans. Clin Chem 2015;61:877-84.
26. Bosworth CR, Levin G, Robinson-Cohen C, Hoofnagle AN, Ruzinski J, Young B, et al. The serum 24, 25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 2012;82:693-700.